Surgical Skill Associated With Colon Cancer Survival Outcomes
Small study assessed surgical skills through submitted videos.
Gastrointestinal Cancer
Statistical Index Suggests That Many ICI Trials Show Uncertain Clinical Benefit
The survival-inferred fragility index of phase 3 trials for immune checkpoint inhibitors suggests that, despite statistical significance, survival data do not show a robust clinical benefit.
Expertscape Publishes Top 10 Specialists in Colorectal Cancer
Expertscape, a web platform that used the PubMed database and its patented algorithm to identify and objectively rank physicians and researchers that excel in the treatment and diagnosis of specific disease states, has released their rankings for U.S. physicians who specialize in the research and treatment of colorectal cancer. Using Expertscape’s rigorous process, Douglas Rex, M.D.,…
USPSTF Supports Initiating CRC Screening at Age 45 in New Draft Recommendation
In response to the rising incidence of CRC in patients younger than 50 years, the USPSTF proposes CRC screening at 45 years as the new clinical standard.
Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Colorectal Cancer in Young People
This fact sheet discusses the rising incidence of colorectal cancer among young adults.
Patients With Colorectal Cancer Report Inadequate Nutritional Support in Survey of Survivors
A cross-sectional survey of patients with CRC revealed a lack of nutritional advice, as well as awareness of its availability.
Dabrafenib and Trametinib Show Promise in Advanced Cholangiocarcinoma
Phase 2 clinical trial shows promising result for dabrafenib and trametinib combination in patients with advanced cholangiocarcinoma with a BRAFV600E mutation.
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials.
First-Line Nivolumab Plus Chemotherapy Improves Survival in Gastric, Gastroesophageal Junction, and Esophageal Cancers
Nivolumab plus chemotherapy prolonged survival of patients with advanced gastric, gastroesophageal junction, and esophageal cancers compared with chemotherapy.
-
Loading...
-
Loading...
Next post in ESMO Virtual Congress 2020
